Theralase Technologies Inc. V.TLT

Ruthenium Complex + NK Cell Immunotherapy

[CancerSlayer]

Utilizing a Ruthenium-based complex to enhance Natural Killer Cell-based immunotherapy against breast cancer.  Below is just another good example of the potential of a Ruthenium complex & other metal-based complexes in treating multiple cancer types...

2022 Jan 11;281:121371.

 doi: 10.1016/j.biomaterials.2022.121371.
 

Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment

Qi Chen 1, Lizhen He 2, Xiaoying Li 3, Ligeng Xu 4, Tianfeng Chen 5

Abstract

Discovery of effective chemical sensitizers to synergize with natural killer cells immunotherapy is urgently desired to overcome its unsatisfactory efficacy in clinic. Herein, we design a series of ruthenium (Ru) polypyridyl complex to systematically explore their potentials in facilitating NK cells treatment. Intriguingly, the chemical structure greatly determines the activity of Ru complexes, while only RuPOP effectively regulates the immuno-suppressors and target proteins within tumor cells. This unique property contributes to its good capability in enhancing the sensitivity of MDA-MB-231 cells to NK cells from cancer patients. Furthermore, besides directly damaging tumor cells, RuPOP pretreatment together with NK cells can also induce robust ROS generation, activate multiple apoptosis-related receptors like TNF-R1, DR5, Fas and maximize the interactions between NK and tumor cells via up-regulating NKG2D and its multiple ligands to trigger caspase 3-dependent apoptosis. Moreover, the combination treatment exhibits high in vivo therapeutic efficacy against breast tumor through boosting the infiltration of NK cells and reducing the protumoral capability of myeloid-derived suppressor cells (MDSC). This study sheds lights for designing metal complexes to potentiate NK cells immunotherapy with clear action mechanisms and provides important information for developing more effective adoptive cell transfer therapy in clinic.

[Legit62]

A day cloer CancerSlayer

[Legit62]

i cant spell , too early, closer sorry

[Eoganacht]

From a pdt point of view this would be called dark toxicity. Ruthenium compounds used as photosensitizers and activated by light demonstrate even more cytotoxicity and the process also produces a powerful immune response.

[99942Apophis]

Eoganacht please accept my gratitude for your insight and translation along with so many here, I have to say we are lucky to have contributors from different sectors of knowledge.

[Tapps21]

Agreed Apop! Always fascinating to read CS and Eogs mystical finds on our beloved company. When is the rest of the world going to find out about this gem? The research and multitude of literature that exists screams we have something special. This has to be our year! The numbers dont lie and progression could be moving at a faster pace imo but who am I.

[CancerSlayer]

Yes, that is correct Eoganacht.  However, much of the excitement for me re: TLT's form of ACT arises not so much from the PDT, but from the metallic compound that makes it all happen.  The fact that this compound has the ability to be cytotoxic/virucidal in the absence of light/irradiation bodes well for the future of this ACT in its many forms (stand-alone, combo, +/- PDT, etc

[Eoganacht]

Time will tell. Up next  - X-ray activation of rutherrin as a gbm treatment. Hopefully this year.

[Gooseybear]

I have a best friend who has gum and my wife lost her best friend to this terrible disease. Praying for his recovery and prompt, effective treatment alternatives other than chemo, radiation and agonizing death.

[Gooseybear]

GBM

[fredgoodwinson]

A paper on that CS : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617654/